AstraZeneca PLC (NASDAQ:AZN) is one of the best pharma stocks to invest in. AstraZeneca PLC (NASDAQ:AZN) received a rating ...
At this year's ASH congress, the results of the phase 1b/2 DURGA-1 of AZD0120 – a dual BCMA and CD19-directed CAR-T therapy – ...
AstraZeneca PLC is rated a Buy due to strong growth, prudent R&D reinvestment, low leverage and resilience. Learn more about ...
Almost four years after penning its first amyloidosis collaboration with Neurimmune, AstraZeneca has returned to ...
Pharmaceutical Technology on MSN
AstraZeneca to expand biomanufacturing in Maryland, US
The Frederick site is expected to generate 900 construction roles and create 200 skilled jobs.
The move would onshore production of its rare disease products at an existing facility in Frederick and build a clinical ...
U.S. health regulators informed senior executives at Merck, Sanofi and AstraZeneca last week that their approved protective RSV treatments for infants would face fresh safety scrutiny following ...
In this morning's Pharmalittle roundup, we're reading about FDA scrutiny of RSV therapies, an AI tool for clinical trials, ...
The pharmaceutical company AstraZeneca can move forward with an addition to one of the buildings on its Frederick campus, ...
Home to 4.8 billion people or 60 percent of the world’s population, Asia accounts for 50 percent of the global cancer ...
FDA approves AstraZeneca's Imfinzi plus FLOT for early gastric and GEJ cancers after Phase 3 data show strong event-free and overall survival benefits.
AstraZeneca's baxdrostat heads into FDA review after Phase 3 data showed strong blood pressure reductions in adults with hard ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results